Literature DB >> 12884926

Optimization of helical tomotherapy treatment plans for prostate cancer.

G Grigorov1, T Kron, E Wong, J Chen, J Sollazzo, G Rodrigues.   

Abstract

Helical tomotherapy (HT) is a novel treatment approach where the ring gantry irradiation geometry of a helical CT scanner is combined with an intensity-modulated megavoltage x-ray fan beam. An inverse treatment planning system (TomoTherapy Inc., Madison) was used to optimize the treatment plans for ten randomly selected prostate patients. Five different sets of margins (2, 5, 7.5 and 10 mm uniform 3D margins and a non-uniform margin of 5 to 10 mm) were employed for the prostate (GTV2) and seminal vesicles (GTV1). The dose distribution was evaluated in targets, rectum, bladder and femoral heads. HT plans are characterized by a rapid dose fall off around the target in all directions resulting in low doses (less than 30% of the dose at ICRU reference point) to the femurs in all cases. Up to a margin of 5 mm for target structures, it was always possible to satisfy the requirements for dose delivery set by RTOG protocol P-0126. Using a 'class solution', HT plans require minimal operator interaction and result in excellent sparing of normal structures in prostate radiotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 12884926     DOI: 10.1088/0031-9155/48/13/306

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  13 in total

1.  High-precision radiotherapy for craniospinal irradiation: evaluation of three-dimensional conformal radiotherapy, intensity-modulated radiation therapy and helical TomoTherapy.

Authors:  D S Sharma; T Gupta; R Jalali; Z Master; R D Phurailatpam; R Sarin
Journal:  Br J Radiol       Date:  2009-07-06       Impact factor: 3.039

2.  Image-guided Radiotherapy Of Esophageal Cancer By Helical Tomotherapy: Acute Toxicity And Preliminary Clinical Outcome.

Authors:  Yi-Jen Chen; Kemp H Kernstine; Stephen Shibata; Dean Lim; David D Smith; Martin Tang; An Liu; Richard D Pezner; Jeffrey Y C Wong
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

3.  Empirical estimation of beam-on time for prostate cancer patients treated on Tomotherapy.

Authors:  Małgorzata Skórska; Tomasz Piotrowski
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-04

4.  Feasibility of concurrent treatment with the scanning ultrasound reflector linear array system (SURLAS) and the helical tomotherapy system.

Authors:  José A Peñagarícano; Eduardo Moros; Petr Novák; Yulong Yan; Peter Corry
Journal:  Int J Hyperthermia       Date:  2008-08       Impact factor: 3.914

5.  Magnetic resonance imaging for adaptive cobalt tomotherapy: A proposal.

Authors:  Tomas Kron; David Eyles; L John Schreiner; Jerry Battista
Journal:  J Med Phys       Date:  2006-10

6.  Tomotherapy as a tool in image-guided radiation therapy (IGRT): theoretical and technological aspects.

Authors:  S Yartsev; T Kron; J Van Dyk
Journal:  Biomed Imaging Interv J       Date:  2007-01-01

7.  Tomotherapy as a tool in image-guided radiation therapy (IGRT): current clinical experience and outcomes.

Authors:  S Yartsev; T Kron; J Van Dyk
Journal:  Biomed Imaging Interv J       Date:  2007-01-01

8.  On the performances of Intensity Modulated Protons, RapidArc and Helical Tomotherapy for selected paediatric cases.

Authors:  Antonella Fogliata; Slav Yartsev; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Rolf Wyttenbach; Glenn Bauman; Luca Cozzi
Journal:  Radiat Oncol       Date:  2009-01-14       Impact factor: 3.481

9.  Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer.

Authors:  Jasper Yuen; George Rodrigues; Kristina Trenka; Terry Coad; Slav Yartsev; David D'Souza; Michael Lock; Glenn Bauman
Journal:  Radiat Oncol       Date:  2008-01-07       Impact factor: 3.481

10.  Psychometric properties of a prostate cancer radiation late toxicity questionnaire.

Authors:  George Rodrigues; Glenn Bauman; Michael Lock; David D'Souza; Jeff Mahon
Journal:  Health Qual Life Outcomes       Date:  2007-05-31       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.